LISTED medical dermatology company Botanix Pharmaceuticals has announced it has signed a research agreement with the University of Queensland's (UQ) Institute for Molecular Bioscience.
The research collaboration is part of an Innovation Connections Grant awarded to Botanix and UQ by the Federal Government's Department of Industry to investigate the antimicrobial activity of Botanix's pipeline product, BTX 1801.
The collaboration will also explore the antimicrobial activity of cannabidiol and Permetrex skin delivery technology.
Clinical studies are planned for the fourth quarter of this year, the company said.
The above article was sent to subscribers in Pharmacy Daily's issue from 20 Jul 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Jul 18
